Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon‐Koo Kang(University of Ulsan), Narikazu Boku(National Cancer Center Hospital East), Taroh Satoh(The University of Osaka), Min‐Hee Ryu(Ulsan College), Yee Chao(Taipei Veterans General Hospital), Ken Kato(National Cancer Center Hospital East), Hyun Cheol Chung(Yonsei University Health System), Jen‐Shi Chen(Chang Gung University), Kei Muro(Aichi Cancer Center), Won Ki Kang(Sungkyunkwan University), Kun‐Huei Yeh(National Taiwan University Hospital), Takaki Yoshikawa(Kanagawa Cancer Center), Sang Cheul Oh(Korea University), Li-Yuan Bai(China Medical University), Takao Tamura(Kindai University), Keun‐Wook Lee(Seoul National University Bundang Hospital), Yasuo Hamamoto(Keio University), Jong Gwang Kim(Kyungpook National University), Keisho Chìn(Japanese Foundation For Cancer Research), Do‐Youn Oh(Seoul National University Hospital), Keiko Minashi(Chiba Cancer Center), Y. Choi(Yonsei University), Masahiro Tsuda(Hyogo Prefectural Cancer Center), Li‐Tzong Chen(National Cheng Kung University Hospital)
Cited by 2,271Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis